Merck Talks About Its Pipeline Post-Singulair
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With its blockbuster asthma drug Singulair going off-patent at the end of the year, Merck is looking to a few key drugs to fill the revenue gap in the coming years, the company said at a recent Deutsche Bank Healthcare conference.
You may also be interested in...
Merck Makes Hepatitis C A Priority
Merck highlighted its hepatitis C franchise at its recent R&D day with analysts and journalists.
Merck Wins Singulair Patent Battle With Teva
A federal court rules that broad scientific presentations do not constitute prior art in this case, a finding that gives Merck three years to consider an OTC switch.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.